Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.70 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.46 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18593898 | 0.90 | TLR8 (0.68) | TLR8TLR7APP | |
| SCHEMBL18593891 | 0.83 | TLR8 (1.00) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL18554053 | 0.82 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL28282506 | 0.78 | TLR8 (0.53) | TLR8TLR7APPDPP4 | |
| SCHEMBL18593906 | 0.76 | TLR8 (0.68) | TLR8TLR7NOS3NOS1NOS2 | |
| SCHEMBL23861660 | 0.75 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL18593892 | 0.73 | TLR8 (1.00) | TLR8TLR7 | |
| Hydrochloric Acid SCHEMBL18554050 | 0.72 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL15147641 | 0.71 | TLR8 (0.51) | TLR8APP | |
| SCHEMBL18459569 | 0.70 | TLR7 (0.80) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2022-01-06 | — | — | US | disclosed |
| US-11130736-B2 | Human TLR8-selective agonists | UNIVERSITY OF KANSAS (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3337481-B1 | QUINOLINE-2-AMINE DERIVATIVES AS HUMAN TLR8-SELECTIVE AGONISTS FOR INCREASING IMMUNE RESPONSE | UNIV KANSAS (US) | 2020-11-11 | — | — | EP | disclosed |
| WO-2017034986-A1 | HUMAN TLR8-SELECTIVE AGONISTS | UNIVERSITY OF KANSAS (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130736-B2 | Human TLR8-selective agonists | TLR7, TLR8, TLR9 | TLR8 2/4885TLR7 1/4885NOS3 2515/4885 |
| US-20220002251-A1 | HUMAN TLR8-SELECTIVE AGONISTS | TLR7, TLR8, TLR9 | TLR8 2/4885TLR7 1/4885NOS3 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.